Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761107
Company: NOVIMMUNE S.A.
Company: NOVIMMUNE S.A.
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| GAMIFANT | EMAPALUMAB-LZSG | 10MG/2ML | INJECTABLE;INJECTION | Prescription | None | No | No |
| GAMIFANT | EMAPALUMAB-LZSG | 50MG/10ML | INJECTABLE;INJECTION | Prescription | None | No | No |
| GAMIFANT | EMAPALUMAB-LZSG | 100MG/20ML | INJECTABLE;INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 11/20/2018 | ORIG-1 | Approval | N/A; Orphan |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761107Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761107Orig1s000TOC.html |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 03/17/2026 | SUPPL-22 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761107s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761107Orig1s0s22ltr.pdf | |
| 06/27/2025 | SUPPL-18 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761107s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761107Orig1s018ltr.pdf | |
| 06/26/2020 | SUPPL-4 | Supplement |
Label is not available on this site. |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 03/17/2026 | SUPPL-22 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761107s022lbl.pdf | |
| 03/17/2026 | SUPPL-22 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761107s022lbl.pdf | |
| 06/27/2025 | SUPPL-18 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761107s018lbl.pdf | |
| 11/20/2018 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf |